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NATuRe IMMuNOLOgy absence of c-Maf. Collectively, our findings showed that in addition to controlling T H 1 and T H 2 responses, c-Maf served a previously unknown, more dominant role in the EAE model, beyond IL-10 expression, by regulating the balance of T H 17 cell responses (Rorc) and Foxp3 + T reg cell responses, which would explain the discordant disease susceptibility between the malaria model and HDM allergy model compared with the EAE model.
The context specificity of c-Maf in the immune response is driven by direct and indirect mechanisms.
To identify the molecular mechanisms whereby c-Maf affects gene regulation in CD4 + T cells in vivo, we used the assay for transposase-accessible chromatin plus sequencing (ATAC-seq) to reveal functionally active genomic regions. Consistent with the RNA-seq profile (Fig. 3a) , hierarchical clustering of ATAC-seq data revealed that the open-chromatin landscape was dominantly driven by each disease and that a distinct separation between Maf-sufficient CD4 + T cells and Maf-deficient CD4 + T cells in their chromatin accessibility was observed only in the malaria model ( Fig. 6a ). This might potentially be explained by the finding of increased chromatin accessibility in the Maf fl/fl Cd4cre condition (Fig. 6b ), which would in part also explain the larger number of dysregulated genes in this model ( Fig. 4a ). Although c-Maf did not itself show evidence of inducing chromatin remodeling ( Fig. 6b ), de novo motif discovery using MEME-ChIP software 37 revealed that the remodeled loci showed enrichment for Runx motif (E value = 3.8 × 10 -92 ) ( Fig. 6b ), which suggested that Runx factors might account for increased open chromatin in the malaria model through their known interactions with epigenetic modifiers 38 . However, such changes in chromatin accessibility were not exclusively responsible for the transcriptional changes observed by RNAseq, since only a small fraction of the differentially expressed genes were associated with altered ATAC-seq peaks in any of the models ( Supplementary Fig. 4 ). Together these data indicated that c-Maf acted via activation and repression of gene expression and that its context-specific action was defined by the accessible chromatin landscape dictated by the type of immune response. We further integrated our RNA-seq data and ATAC-seq data with data obtained by analysis of c-Maf with chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 7 and motif data to identify genes that were targets of c-Maf; these results were confirmed by BETA software (which integrates ChIPseq analyses and gene-expression data to identify target genes) 39 ( Supplementary Fig. 5 , Supplementary Table 5 and Supplementary Data). Differentially expressed genes showed enrichment for 
Fig. 2 | c-Maf deficiency in CD4 + T cells affects susceptibility to disease in a context-specific manner. a-c,
Protocol for the models with Maf fl/fl and Maf fl/fl Cd4-cre mice: intraperitoneal (i.p.) injection of Plasmodium chabaudi-infected red blood cells (RBC) into mice to induce malaria (a); treatment of mice intraperitoneally (i.p.) with HDM in alum and intratracheally (i.t.) with HDM to induce allergy (b); and treatment of mice intraperitoneally (i.p.) with myelin oligodendrocyte glycoprotein (MOG) in complete Freund's adjuvant (CFA) plus pertussis toxin (PTx) to induce EAE disease (c). d, Change in body weight (left), body temperature (middle) and parasitemia (right) at various times (horizontal axis) during infection of mice (key) with P. chabaudi as in a (n = 14 mice per group). e, Total cells and eosinophils (differential counts of Giemsa-stained cells) in the bronchoalvelolar fluid (BALF) of mice (key) after treatment with PBS or HDM challenge as in b (horizontal axis) (left two plots; n = 5 experiments); microscopy of lung sections from such mice (above images and left margin), stained with H&E or with Alcian blue plus periodic acid-Schiff (AB-PAS) (below images) (middle images); and cumulative total inflammation score (from H&E analysis) and mucous score (from AB-PAS analysis) in such mice (right two plots). Each symbol (left and right) represents an individual mouse. Scale bars (middle), 500 μ m. *P < 0.05 (two-tailed Mann-Whitney test). f, Change in body weight (left) and clinical score (middle; includes linear regression) at various times (horizontal axis) during the induction of EAE as in c (n = 10 mice per group), and distribution of disease severity in such mice (right) (key: no EAE (None), score < 2; mild EAE, score = 2-3; severe EAE, score > 4; n = 28 mice per group). *P ≤ 0.035 (F-test). Data are from (d, e (left and right), f) or representative of (e (middle)) three biological replicate experiments per disease model (mean ± s.e.m. in d,f; mean ± s.d. in e).
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putative c-Maf-binding sites ( Supplementary Table 6 ), which indicated that c-Maf was able to have direct effects and was responsible for the transcriptional changes seen. Specifically, the combined evidence of open chromatin coincident with binding of c-Maf to the Il10 locus confirmed c-Maf as a direct positive regulator of Il10 in vivo ( Fig. 6c,d ). However, although we found that Il4 and Rorc were Cebpa Tnfrsf13b 
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NATuRe IMMuNOLOgy also direct targets of c-Maf, the effect of c-Maf on the expression of Tbx21 and Foxp3 was indirect, with no evidence of direct binding to these loci ( Fig. 6c,d and Supplementary Fig. 6 ). Thus, the observed changes in Rorc expression relative to Foxp3 expression that resulted from c-Maf deficiency were probably due to indirect mechanisms.
IL-2 is a c-Maf target.
To identify candidate TFs responsible for the indirect effects of c-Maf, we applied 'bivariate genomic footprinting' (BaGFoot) software 40 to the ATAC-seq data to assess changes in global TF activity, as measured by changes in TF 'footprint depth' and accessibility of flanking motifs ( Fig. 7a and Supplementary  Table 7 ). TF-binding site motifs that were significant outliers from the multivariate distribution that showed TF binding in the absence of c-Maf different from that in its presence (the control condition) were predominantly context-specific and were more abundant in the malaria model than in the HDM allergy model or EAE model ( Fig. 7a ), in line with the expression data ( Fig. 4a ). Moreover, the accessible genomic neighborhood of differentially expressed genes showed significant enrichment for most of these TF motifs, compared with the non-differentially expressed genes ( Supplementary  Table 8 ), in the three model diseases after deletion of c-Maf. De novo motif discovery (by MEME-ChIP) identified the motif for the Runx family of TFs as the top match in differentially accessible ATAC-seq peaks in the malaria model (E value = 3.8 × 10 -92 ) (Fig. 6b ). The remodeled loci showed enrichment for the Runx motif (Fig. 6b ), and Runx showed enhanced binding ( Fig. 7a) and increased expression (Figs. 3a and 4b-d and Supplementary  Table 3 ) in Maf fl/fl Cd4-cre mice exclusively in the malaria model. Furthermore, Runx showed a more significant effect on differentially expressed genes than did c-Maf itself ( Supplementary Table 8 ).
Thus, Runx might have contributed to the increased pathology in the malaria model by its reported effects on IFN-γ production 41 . The AP-1 family members BATF, Jund, Jun and Junb ( Fig. 7a and Supplementary Table 8 ), which are known to directly interact with c-Maf 42 , might further contribute to changes in gene expression, including regulation of Il10 9 . Bhlhe40, a known negative regulator of IL-10 43 that we found was upregulated in Maf-deficient CD4 + T cells ( Supplementary Table 3 ), also seemed to additionally contribute to the indirect effects of c-Maf in the malaria model and HDM allergy model, as shown by the analysis with BaGFoot software ( Fig. 7a and Supplementary Table 8 ).
In contrast to the context-specific effects on TFs, the NFAT2 motif showed significant differences in the genome-wide footprints ( Fig. 7b ) and contributed to changes in gene expression in all three disease models ( Fig. 7a and Supplementary Table 8 ). On the basis of the well-known role of NFAT in the regulation of Il2 expression 44 , we concluded that both Il2 and Il2ra were potential direct targets of c-Maf (Fig. 7c ). Since IL-2 is known to regulate Foxp3 + T reg cells 5, 45 and T H 17 cells 46 
Discussion
Here we combined comprehensive transcriptional, epigenomic and TF-binding analyses of CD4 + T cells from mice with Maf-deficiency targeted to such cells to show that c-Maf provides a common mechanism for direct transcriptional regulation of Il10 expression in CD4 + T cells in vivo in models of T H 1, T H 2 and T H 17 responses. Furthermore, we identified a broad context-specific gene-expression program regulated by c-Maf beyond its effects on IL-10, which explained the unexpected diverse effects on each disease phenotype. We demonstrated that c-Maf in fact functioned by both direct mechanisms and indirect mechanisms to regulate gene expression and to control the effector phenotype in T H 1 and T H 2 responses, which, in conjunction with IL-10, might reinforce the distinct disease outcomes observed. In the malaria model, T H 1 cell-associated genes were regulated indirectly by a c-Maf-driven gene network that reinforces T H 1 cell activity to combat pathology. For example, Bhlhe40, which encodes a molecule associated with circadian rhythm 31 
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Further inference of c-Maf regulatory networks showed that a proportion of the transcriptional changes seen could have been a result of the increased NFAT activity observed in Maf-deficient CD4 + T cells across all disease models. Given the well-known role of NFAT in the regulation of Il2 expression 44 and our finding that both Il2 and Il2ra were direct targets of c-Maf, we confirmed the predictions of the regulatory networks to demonstrate a role for c-Maf as a negative regulator of IL-2. Collectively our findings suggest that by negatively regulating Il2 expression, c-Maf has overarching contextspecific effects on immune responses, on the one hand limiting T H 1 and T H 2 responses that depend strongly on IL-2 and on the other hand allowing the development of a T H 17 response by regulating Rorc expression and Foxp3 + T reg cells. These findings are in apparent contrast to published studies showing that deletion of c-Maf targeted to Foxp3 + cells results in fewer Rorc + Foxp3 + T reg cells 19, 20 , which, given the nature of their systems, could not reveal the more global effects of c-Maf on gene expression in CD4 + T cells during distinct immune responses that we have reported here. Despite that, these findings reinforce our concept that c-Maf has context-specific effects on the immune response. Together our findings have demonstrated a broad yet contextspecific role for c-Maf in regulating gene expression that allows each type of T cell effector immune response to occur in a controlled yet effective manner. Our study has also highlighted the utility of genome-wide analyses that span multiple layers of transcriptional regulation to reveal and validate gene networks.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0083-5. 
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Experimental design 1. Sample size
Describe how sample size was determined.
Animal sample size estimates were determined using previous studies and/or pilot studies using 4-5 animals per group and guided by the 3R principle.
Data exclusions
Describe any data exclusions.
No data exclusions were performed.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Unless otherwise stated, experimental replicates were included in analysis e.g. in RNA-Seq and ATAC-Seq analysis with appropriate statistical methods applied. Where representative data were shown, the experimental findings were reproduced with similar results.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not carried out in this study. Animals were age and sex matched between experimental groups in order to account for covariates.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was performed during bioinformatic data analysis, using using unsupervised methods to identify differences in transcriptomic and genomic profiles. Blinding was not performed during data collection. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
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Flow Cytometry: Depending on the cytometer, data was collected using either Diva or BD FACSuiteTM (BD LSR II, BD LSRFortessaTM , BD Fusion or BD FACSVerse) or Summit (MoFloTM XDP) Softwares. All data were analysed using Flow Jo software (Treestar).
Histology:
OlyVIA software was used to view and score histology slides.
RNA-Seq:
For in vitro differentiated CD4+ T cell analysis, alignment of reads to the mouse transcriptome (mm10) and absolute quantification of the genes was performed in Strand NGS (version 2.0) with default parameters (95% identity, max 5% gaps, 1 read only if duplicated, ignoring reads with more than 5 matches), guided by RefSeq annotations (2013.04.01) (in vitro TH cells) or Ensembl (2014.04.01) (ex vivo CD4+ T cells). For ex vivo CD4+ T cell analysis, all analyses were performed with the R statistical package version 3.3.1 (2016) and Bioconductor libraries version 3.3. Proportional Venn diagrams were generated using eulerAPE webtool. Ingenuity Pathway Analysis (IPA) (QIAGEN Redwood City, www.qiagen.com/ingenuity) was used for gene family annotation and to obtain gene-gene interactions used to generate networks, which were then visualized with Cytoscape (version 3.4.0).
ATAC-Seq:
FastQC_0.11.5: for overall quality assessment Skewer 0.2.2: sequencing quality control IGV_2.3.97: genome browser visual inspection of ATAC-seq peaks in BED format SAMtools 1.3.1 for alignment QC (discarded alignments with a mapQ < 30) BWA-MEM: map pair-end reads to mm10 BEDTools 2.26.0: convert alignments from bam to bed format Awk: command line tool. Used to remove alignments done to mitochondrial DNA, shift reads in the forward strand by + 4bp or reverse strand by -5 bp , and to remove fragments with a size >99bp. MACS2 2.1.1: peak-calling Diffbind 2.0.2: peak read quantification to test for differential changes in chromatin accessibility. BaGFoot: test for differential TF activity based on changes in Tn5 insertions on motif matching sites. Other graphs and statistics: GraphPad Prism Version 6 was used to plot bar graphs, box and whisker graphs and line graps as well as to perform experimental statistical analysis.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party. b. Describe the method of cell line authentication used. Cell lines were not used in this study. c. Report whether the cell lines were tested for mycoplasma contamination.
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Cell lines were not used in this study.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
All mice were bred and maintained under specific pathogen-free conditions at The Francis Crick Institute, Mill Hill laboratory according to the Home Office UK Animals (Scientific Procedures) Act 1986 and mostly used at 8-16 weeks of age. C57BL/6 (females) wild-type mice were bred in-house Foxp3RFP IL-10GFP (females) were provided by R.A. Flavell. C-Maffl/ fl mice provided by M. Sieweke and C. Birchmeier, were backcrossed to C57Bl/6 mice for ten generations and subsequently crossed to CD4Cre mice to generate c-Maffl/flCD4Cre mice, with c-Maffl/fl mice used as controls (malaria -males, HDM allergy -females, EAE -either males or females). Bcl6fl/fl were provided by T. 
Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodological details 5 . Describe the sample preparation. Figure 1 : Naïve CD4+CD62L+CD44loCD25-T cells were purified from C57BL/6 mouse spleens by negative enrichment of CD4+ T cells, sorted on a MoFloTM XDP cytometer (Beckman Coulter) using CD4 e450, CD62L PECy7, CD44 PE and CD25 APC antibodies (all eBioscience) and differentiated in vitro under different TH conditions. Treg cells were sorted from IL-10GFPFoxp3RRFP dual-reporter mouse spleens directly ex vivo by negative enrichment of CD4+ T cells and sorting of CD4+ (CD4 APCe780, eBioscience) Foxp3RFP+IL-10GFP-or Foxp3RFP+IL-10GFP+ cells.
After differentiation, T cells were re-stimulated with anti-CD3 and anti-CD28 at 2 ug/ml each (all TH but TH17) or PDBU (Sigma-Aldrich) and Ionomycin (Calbiochem) at 500 ng/ml each (TH17) for 4 hours, with Brefeldin A (10 ug/ml, Sigma-Aldrich) added for the last 2 or 4 hours of culture, respectively. Surface markers were stained in PBS together with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Molecular Probes). For intracellular cytokine detection, cells were fixed with 2% formaldehyde, permeabilized with permeabilization buffer (eBioscience) and stained with: anti-IL-2 APC-Cy7 (BD), anti-IFNg PECy7 (BD) and anti-IL-4 PE, anti-IL-10 APC, anti-IL17A FITC (eBioscience). For Foxp3 staining, cells were fixed with Fixation/Permeabilization buffers and stained with anti-Foxp3 PE (eBioscience).
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All ATAC-seq samples were sequenced using Illumina HiSeqs2500, paired-end. Data is described as follows: Sample ID -sequencing depth, length of reads. Quantity of reads remaining after
